{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:44:22Z","timestamp":1771332262893,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The 2018\/2023 ESC\/ESH Guidelines underlined a gap how baseline cardiovascular disease (CVD) risk predicted blood pressure (BP) lowering benefits. Further, 2017 ACC\/AHA Guideline and 2021 WHO Guideline recommended implementation studies about intensive BP control. Now, to bridge these guideline gaps, we conducted a post hoc analysis to validate whether the baseline CVD risk influences the effectiveness of the intensive BP control strategy, which was designed by China Rural Hypertension Control Project (CRHCP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a post hoc analysis of CRHCP, among which participants were enrolled except those having CVD history, over 80\u00a0years old, or missing data. Subjects were stratified into quartiles by baseline estimated CVD risk and then grouped into intervention and usual care group according to original assignment in CRHCP. Participants in the intervention group received an integrated, multi-faceted treatment strategy, executed by trained non-physician community health-care providers, aiming to achieve a BP target of\u2009&lt;\u2009130\/80\u00a0mmHg. Cox proportional-hazards models were used to estimate the hazard ratios of outcomes for intervention in each quartile, while interaction effect between intervention and estimated CVD risk quartiles was additionally assessed. The primary outcome comprised myocardial infarction, stroke, hospitalization for heart failure, or CVD deaths.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Significant lower rates of primary outcomes for intervention group compared with usual care for each estimated CVD risk quartile were reported. The hazard ratios (95% confidence interval) in the four quartiles (from Q1 to Q4) were 0.59 (0.40, 0.87), 0.54 (0.40, 0.72), 0.72 (0.57, 0.91) and 0.65 (0.53, 0.80), respectively (all <jats:italic>P<\/jats:italic>s\u2009&lt;\u20090.01). There\u2019s no significant difference of hazard ratios by intervention across risk quartiles (<jats:italic>P<\/jats:italic> for interaction\u2009=\u20090.370). Only the relative risk of hypotension, not symptomatic hypotension, was elevated in the intervention group among upper three quartiles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Intensive BP lowering strategy designed by CRHCP group was effective and safe in preventing cardiovascular events independent of baseline CVD risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial is registered with ClinicalTrials.gov, NCT03527719.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-024-03494-w","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:07:28Z","timestamp":1718881648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of baseline cardiovascular risk on the outcomes of intensive blood pressure intervention: a post hoc analysis of the China rural hypertension control project"],"prefix":"10.1186","volume":"22","author":[{"given":"Guozhe","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanxiang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danxi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"3494_CR1","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","volume":"383","author":"E Rapsomaniki","year":"2014","unstructured":"Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1\u00b725 million people. Lancet. 2014;383:1899\u2013911.","journal-title":"Lancet"},{"key":"3494_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70:1\u201325.","journal-title":"J Am Coll Cardiol"},{"key":"3494_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/jhh.2008.16","volume":"22","author":"J Lee","year":"2008","unstructured":"Lee J, Ma S, Heng D, et al. Hypertension, concurrent cardiovascular risk factors and mortality: the Singapore Cardiovascular Cohort Study. J Hum Hypertens. 2008;22:468\u201374.","journal-title":"J Hum Hypertens"},{"key":"3494_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0140-6736(05)70240-3","volume":"365","author":"R Jackson","year":"2005","unstructured":"Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual\u2019s absolute cardiovascular risk. Lancet. 2005;365:434\u201341.","journal-title":"Lancet"},{"key":"3494_CR5","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.jacc.2017.02.066","volume":"69","author":"P Muntner","year":"2017","unstructured":"Muntner P, Whelton PK. Using predicted cardiovascular disease risk in conjunction with blood pressure to guide antihypertensive medication treatment. J Am Coll Cardiol. 2017;69:2446\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"3494_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2215\/CJN.09410620","volume":"15","author":"SB Ascher","year":"2020","unstructured":"Ascher SB, Ix JH. Intensive blood pressure lowering should be the goal for most individuals at high risk of cardiovascular disease irrespective of albuminuria. Clin J Am Soc Nephrol. 2020;15:1081\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3494_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1161\/HYPERTENSIONAHA.121.18192","volume":"79","author":"A Al-Makki","year":"2022","unstructured":"Al-Makki A, DiPette D, Whelton PK, et al. Hypertension pharmacological treatment in adults: a world health organization guideline executive summary. Hypertension. 2022;79:293\u2013301.","journal-title":"Hypertension"},{"key":"3494_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269\u2013324.","journal-title":"Hypertension"},{"key":"3494_CR9","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"12","key":"3494_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia Chairperson","year":"2023","unstructured":"Mancia Chairperson G, Kreutz Co-Chair R, Brunstr\u00f6m M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"key":"3494_CR11","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"3494_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2018.01.074","volume":"71","author":"RA Phillips","year":"2018","unstructured":"Phillips RA, Xu J, Peterson LE, et al. Impact of cardiovascular risk on the relative benefit and harm of intensive treatment of hypertension. J Am Coll Cardiol. 2018;71:1601\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"3494_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamacardio.2016.2861","volume":"1","author":"AM Navar","year":"2016","unstructured":"Navar AM, Pencina MJ, Peterson ED. Assessing cardiovascular risk to guide hypertension diagnosis and treatment. JAMA Cardiol. 2016;1:864\u201371.","journal-title":"JAMA Cardiol"},{"key":"3494_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"3494_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(22)02603-4","volume":"401","author":"J He","year":"2023","unstructured":"He J, Ouyang N, Guo X, et al. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023;401:928\u201338.","journal-title":"Lancet"},{"key":"3494_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ajh\/hpab038","volume":"34","author":"Y Sun","year":"2021","unstructured":"Sun Y, Li Z, Guo X, et al. Rationale and design of a cluster randomized trial of a village doctor-led intervention on hypertension control in China. Am J Hypertens. 2021;34:831\u20139.","journal-title":"Am J Hypertens"},{"key":"3494_CR17","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73.","journal-title":"Circulation"},{"key":"3494_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/cid\/ciac731","volume":"76","author":"AN Muiru","year":"2023","unstructured":"Muiru AN, Madden E, Scherzer R, et al. Effect of adopting the new race-free 2021 chronic kidney disease epidemiology collaboration estimated glomerular filtration rate creatinine equation on racial differences in kidney disease progression among people with human immunodeficiency virus: an observational study. Clin Infect Dis. 2023;76:461\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3494_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2478\/jtim-2022-0012","volume":"10","author":"B Song","year":"2022","unstructured":"Song B, Bie Y, Feng H, Zhao F, et al. Inflammatory factors driving atherosclerotic plaque progression new insights. J Transl Int Med. 2022;10(1):36\u201347.","journal-title":"J Transl Int Med."},{"key":"3494_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"3494_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775\u201381.","journal-title":"JAMA Cardiol"},{"key":"3494_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","volume":"384","author":"BPLTT Collaboration","year":"2014","unstructured":"Collaboration BPLTT. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591\u20138.","journal-title":"Lancet"},{"key":"3494_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/2047487318800741","volume":"26","author":"A Attar","year":"2019","unstructured":"Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. Eur J Prev Cardiol. 2019;26:238\u201345.","journal-title":"Eur J Prev Cardiol"},{"key":"3494_CR24","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2021.02.058","volume":"77","author":"AP Bress","year":"2021","unstructured":"Bress AP, Greene T, Derington CG, et al. Patient selection for intensive blood pressure management based on benefit and adverse events. J Am Coll Cardiol. 2021;77:1977\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"3494_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.113.02089","volume":"63","author":"G Reboldi","year":"2014","unstructured":"Reboldi G, Angeli F, de Simone G, et al. Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension. 2014;63:475\u201382.","journal-title":"Hypertension"},{"key":"3494_CR26","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr","year":"2002","unstructured":"Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421\u201331.","journal-title":"JAMA."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03494-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:14:54Z","timestamp":1718882094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03494-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03494-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the First Hospital of China Medical University and all collaborating centers (KLS20181582). All participants have signed informed consent at screening visits.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest regarding the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}